Lupin has decided not to pursue the MoU the company signed with Aspen Pharmacare Holdings in February 2006 for a 50:50 joint venture for the development, manufacture and global marketing (except US, South Africa & India Trade) of a range of Anti-TB products.According to a release issued by Lupin to BSE today, both the parties have mutually agreed not to pursue the MoU."The companies will continue to collaborate for TB-related products market in the Republic of South Africa as per the agreement entered in September 2005," the release added.
